Improving Healthspan and Increasing Lifespan
Perseus SENOLYTIX™ is an affiliated of SENOTHERAPEUTIX™
Aging is the primary risk factor for chronic diseases, including Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, along with many others, including cancer. Our affiliated companies’ lead programs, focused on proprietary gerotherapeutic peptides, have the remarkable ability to rejuvenate naturally aged mice via two separate mechanisms, both targeting the MMP (ΔΨm) to dramatically eliminate senescent cells throughout the body in the medium to longer term, and to enhance the efficiency of mitochondrial function in aging cells in general, beginning in the short term, with no apparent adverse side effects. These peptides work via a completely novel mechanism of action, targeting the lower and declining ΔΨm found in senescent cells compared to non-senescent cells, and in aging cells in general, that develops as we age.
Cancer cells also have less capacity to maintain the mitochondrial ΔΨm compared with normal cells, suggesting ΔΨm as a selective functional target for cancer too. In preliminary studies, we found our gerotherapeutic peptides to have significant activity against TOM-1, a highly aggressive human Acute Lymphoblastic Leukemia cell line harboring a wild type ABL1 mutation.
Perseus SENOLYTIX is developing novel gerotherapeutic peptides to target cancer via this novel mechanism. In pre-clinical studies, our peptides have been administered at escalating doses for over 16 weeks with no evidence of toxicity, opening the door for a potential safe and effective new class of cancer therapeutics.
Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine, have been spun out into three wholly owned subsidiaries of SENOTHERAPEUTIX, Inc.: (1) Eos SENOLYTIX, a longevity company developing novel gerotherapeutic peptides to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel gerotherapeutic peptides to target cancer via this same novel mechanism as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan. Visit our affiliate Companies to learn more about them!
